Trials / Completed
CompletedNCT02312882
Tofacitinib for the Treatment of Alopecia Areata and Its Variants
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.
Detailed description
This study is an open-label pilot study. Participants will be treated with oral tofacitinib for 3 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tofacitinib | Tofacitinib 5 mg tablet taken by mouth twice a day. |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2014-12-09
- Last updated
- 2017-11-06
- Results posted
- 2017-11-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02312882. Inclusion in this directory is not an endorsement.